RECRUITING

Study of BHV-1400 in IgA Nephropathy

Description

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

Conditions

IgA Nephropathy
Talk to us

Related Conditions:

IgA Nephropathy

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy

Study of BHV-1400 in IgA Nephropathy

Condition
IgA Nephropathy
Intervention / Treatment

-

Contacts and Locations

Miami Lakes

Site-003, Miami Lakes, Florida, United States, 33016

Pembroke Pines

Site-005, Pembroke Pines, Florida, United States, 33029

Chesterfield

Site-006, Chesterfield, Missouri, United States, 63017

Dakota Dunes

Site-002, Dakota Dunes, South Dakota, United States, 57049

Houston

Site-004, Houston, Texas, United States, 77099

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Participants must have biopsy-confirmed IgA Nephropathy
  • 1. Any secondary IgAN
  • 2. Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Biohaven Therapeutics Ltd.,

Study Record Dates

2026-07